Clarivate Epidemiology’s coverage of diabetic retinopathy (DR) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of DR for each…
Clarivate Epidemiology’s coverage of HD comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of HD for each country, as well as…
Clarivate Epidemiology’s coverage of primary sclerosing cholangitis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of mesothelioma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
Clarivate Epidemiology’s coverage of acute prophylaxis for venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets…
Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of PH…
Clarivate Epidemiology's coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed prevalence…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Pulmonary hypertension disease patient populations, covering 171…
Male hypogonadism is characterized by low serum testosterone and impaired spermatogenesis. Primary male hypogonadism results from an intrinsic abnormality in the testes, while secondary male…
Pulmonary hypertension (PH) constitutes a group of rare diseases, including pulmonary arterial hypertension (PAH), yet the commercial potential for novel drugs approved for PH indications is…
The total number of diagnosed incident cases of liposarcoma in the countries under study will increase by 17% over the 20-year forecast period. For the year 2022, liposarcoma of the HNTE…
Clarivate Epidemiology’s coverage of liposarcoma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
Clarivate’s Epidemiology's coverage of Soft tissue sarcoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Soft…
Clarivate Epidemiology's coverage of painful diabetic neuropathy (PDN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
Clarivate Epidemiology's coverage of dyslipidemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dyslipidemia for each…